CompletedNCT04451187
A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder
Medication studyAges 21–80Belgium + GermanyDepression
Understand this study
Who was this study for?
Listed age limits: 21 years to 80 years.
- Listed locations
- Alken and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: July 16, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 63
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Belgium, Germany
- Age range
- From 21 Years to 80 Years
- Official registry ID
- NCT04451187
- Official title
Show the full official title
A Multicentric, Randomized, Double-Blind, Placebo- and Positive-Controlled 4-way Crossover Study to Evaluate the Effects of Single and Repeated Administration of Oral Seltorexant as an add-on Medication to an Antidepressant on On-Road Driving Performance in Participants With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedAlken, Belgium · Aachen, Germany
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Seltorexant Dose 1, Seltorexant Dose 2, Placebo and Zopiclone.
Who was this study for?
Listed age limits: 21 years to 80 years.
Want to explore more studies?
Explore studiesRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide